![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. Acetate, Mitoxantrone
2. Cl 232325
3. Cl-232325
4. Cl232325
5. Dhaq
6. Hydrochloride, Mitoxantrone
7. Mitoxantrone Acetate
8. Mitoxantrone Hydrochloride
9. Mitozantrone
10. Mitroxone
11. Novantron
12. Novantrone
13. Nsc 279836
14. Nsc 287836
15. Nsc 299195
16. Nsc 301739
17. Nsc 301739d
18. Nsc-279836
19. Nsc-287836
20. Nsc-299195
21. Nsc-301739
22. Nsc-301739d
23. Nsc279836
24. Nsc287836
25. Nsc299195
26. Nsc301739
27. Nsc301739d
28. Onkotrone
29. Pralifan
30. Ralenova
1. 65271-80-9
2. Mitoxanthrone
3. Mitozantrone
4. Dhaq
5. Mitoxantron
6. Novantrone
7. Mitoxantrona
8. Mitoxantronum
9. Mitoxantrone [inn]
10. Misostol
11. Nsc 279836
12. Nsc-279836
13. Dhad
14. Nsc279836
15. 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
16. Mitoxantrone (inn)
17. Mitoxantrone Free Base
18. 1,4-bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
19. Bz114nvm5p
20. 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
21. 1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
22. 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
23. 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
24. Mls002703044
25. Chebi:50729
26. 65271-80-9 (free Base)
27. Mfcd00242942
28. 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-
29. Mitoxantronum [inn-latin]
30. Mitoxantrona [inn-spanish]
31. Nsc299195
32. Nsc301739
33. 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione
34. 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
35. Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-
36. Mix
37. 1,4-dihydroxy-5,8-bis[2-[(1,1,2,2-tetradeuterio-2-hydroxyethyl)amino]ethylamino]anthracene-9,10-dione
38. Mls001333711
39. 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-
40. Misostol (tn)
41. 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione
42. Ccris 7604
43. Ncgc00015693-02
44. Mitoxantrone (free Base)
45. Smr000058480
46. Mitoxantrone [inn:ban]
47. Cas-70476-82-3
48. Unii-bz114nvm5p
49. Dhaq (*diacetate Salt*)
50. Brn 2795126
51. Sr-01000076001
52. Mitoxantrone Base
53. 1,4-dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
54. 2fum
55. 1,4-dihydroxy-5,8-bis(2-(2-hydroxyethylamino)ethylamino)anthracene-9,10-dione
56. 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthracene-9,10-dione
57. Immunex (salt/mix)
58. Spectrum_001655
59. Chembl58
60. Prestwick0_000385
61. Prestwick1_000385
62. Prestwick2_000385
63. Prestwick3_000385
64. Spectrum2_000908
65. Spectrum3_001590
66. Spectrum4_000866
67. Spectrum5_001205
68. Lopac-m-6545
69. Mitoxantrone [mi]
70. Mitoxantrone [iarc]
71. Cid_4212
72. Neuro_000153
73. Schembl3000
74. 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
75. Mitoxantrone [vandf]
76. Bidd:pxr0181
77. Lopac0_000779
78. Bspbio_000569
79. Bspbio_003160
80. Kbiogr_001531
81. Kbioss_002135
82. Divk1c_000516
83. Mitoxantrone [who-dd]
84. Spbio_000756
85. Spbio_002490
86. Bpbio1_000627
87. Gtpl7242
88. Dtxsid4046947
89. Bdbm67690
90. Cid_5458171
91. Kbio1_000516
92. Kbio2_002135
93. Kbio2_004703
94. Kbio2_007271
95. Kbio3_002660
96. Ninds_000516
97. Hms2090d05
98. Hms3655e20
99. Kuc108634n
100. Bcp02861
101. Zinc3794794
102. Ccg-36371
103. S1889
104. Stk631833
105. Mitoxantrone Hydrochloride (salt/mix)
106. Akos005564036
107. Bcp9000931
108. Db01204
109. Ksc-19-204
110. Sdccgsbi-0050757.p004
111. Idi1_000516
112. Smp2_000179
113. Ncgc00015693-01
114. Ncgc00015693-03
115. Ncgc00015693-04
116. Ncgc00015693-05
117. Ncgc00015693-06
118. Ncgc00015693-08
119. Ncgc00015693-13
120. Ncgc00015693-23
121. Ncgc00162251-01
122. As-35321
123. Hy-13502
124. Mitoxantrone, Mitoxantrone Hydrochloride, Mitoxantrone Dihydrochloride, Mitoxanthrone Hydrochloride
125. Nci60_002276
126. Nci60_002535
127. Smr001549953
128. Sy226320
129. Sbi-0050757.p003
130. Ab00053716
131. Ft-0630752
132. Ft-0672423
133. M3133
134. Sw196745-6
135. Vu0244399-2
136. 71m809
137. D08224
138. Ab00053716-18
139. Ab00053716-19
140. Ab00053716-22
141. Ab00053716_23
142. Ab00053716_24
143. Q239426
144. Sr-01000076001-7
145. Brd-k21680192-001-01-5
146. Brd-k21680192-001-11-4
147. Brd-k21680192-300-05-2
148. Brd-k21680192-300-07-8
149. Brd-k21680192-300-09-4
150. Brd-k21680192-300-10-2
151. Brd-k21680192-300-12-8
152. 1,4-bis[2-(2-hydroxyethylamino)-ethylamino]-5,8-dihydroxyanthraquinone
153. 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone
154. 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone
155. 9, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] Amino]-
156. 1,4-bis[[2-[(2-hydroxyethyl)amino]ethyl]imino]-1,4-dihydroanthracene-5,8,9,10-tetrol
157. 1,4-dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone
158. 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-9,10-anthraquinone;hydrochloride
159. 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;hydrochloride
160. 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-bis(oxidanyl)anthracene-9,10-dione;hydrochloride
161. Mitoxantrone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
Molecular Weight | 444.5 g/mol |
---|---|
Molecular Formula | C22H28N4O6 |
XLogP3 | 1 |
Hydrogen Bond Donor Count | 8 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 12 |
Exact Mass | 444.20088463 g/mol |
Monoisotopic Mass | 444.20088463 g/mol |
Topological Polar Surface Area | 163 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 571 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
FDA Label
Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
L01DB07
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01D - Cytotoxic antibiotics and related substances
L01DB - Anthracyclines and related substances
L01DB07 - Mitoxantrone
Absorption
Poorly absorbed following oral administration
Volume of Distribution
1000 L/m2
Clearance
21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
Hepatic
75 hours
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.